[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C][=Branch1][C][=O][N][Branch1][C][C][C][Branch2][Branch1][Ring2][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][C][C][C@@][Branch2][Ring1][=Branch1][C][C][C][N][Branch1][Ring2][C][Ring1][=Branch1][C][=Branch1][C][=O][C][=C][C][=C][C][=C][Ring1][=Branch1][C][=C][C][=Branch1][=Branch2][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][Cl][Cl][C][=C][C][=C][C][=C][Ring1][=Branch1]"}, {"from": "gpt", "value": "The molecule is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System (CNS) disorders. In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. This follows an earlier decision to discontinue development of eplivanserin for schizophrenia."}]